ACADIA Pharmaceuticals Inc.
US ˙ NasdaqGS ˙ US0042251084

Introduction

This page provides a comprehensive analysis of the known insider trading history of Schneyer Mark C.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Schneyer Mark C. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ACAD / ACADIA Pharmaceuticals Inc. EVP, CHIEF FINANCIAL OFFICER 40,130
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Schneyer Mark C.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACAD / ACADIA Pharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACAD / ACADIA Pharmaceuticals Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACAD / ACADIA Pharmaceuticals Inc. Insider Trades
Insider Sales ACAD / ACADIA Pharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACAD / ACADIA Pharmaceuticals Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2023-11-20 ACAD Schneyer Mark C. 5,108 22.6400 5,108 22.6400 115,645 338 14.2900 -42,652 -36.88
2023-06-08 ACAD Schneyer Mark C. 974 25.0200 974 25.0200 24,369
2023-05-17 ACAD Schneyer Mark C. 15,310 22.5000 15,310 22.5000 344,475
2023-04-06 ACAD Schneyer Mark C. 1,916 18.1600 1,916 18.1600 34,795
2023-02-24 ACAD Schneyer Mark C. 577 18.7800 577 18.7800 10,836
2022-06-09 ACAD Schneyer Mark C. 653 17.9095 653 17.9095 11,695
2022-02-23 ACAD Schneyer Mark C. 553 23.8000 553 23.8000 13,161

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACAD / ACADIA Pharmaceuticals Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Schneyer Mark C. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-19 2025-08-18 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -22,000 40,130 -35.41 25.18 -554,024 1,010,590
2025-05-19 2025-05-16 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -2,000 62,130 -3.12 25.00 -50,000 1,553,250
2025-05-02 2025-05-02 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -3,498 62,773 -5.28 14.60 -51,071 916,486
2025-05-02 2025-05-01 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 6,815 66,271 11.46
2025-04-08 2025-04-08 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -2,708 59,456 -4.36 14.82 -40,133 881,138
2025-04-08 2025-04-05 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 5,275 62,164 9.27
2025-03-26 2025-03-26 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -3,171 56,889 -5.28 17.05 -54,066 969,957
2025-03-26 2025-03-25 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 6,178 60,060 11.47
2025-02-25 2025-02-24 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -773 53,882 -1.41 19.96 -15,429 1,075,485
2025-02-25 2025-02-23 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 1,353 54,655 2.54
2024-11-19 2024-11-19 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -10,259 53,302 -16.14 16.81 -172,454 896,007
2024-11-19 2024-11-17 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 9,913 63,561 18.48
2024-11-19 2024-11-17 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 9,913 63,561 18.48
2024-08-20 2024-08-19 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -9,733 43,735 -18.20 15.28 -148,720 668,271
2024-08-20 2024-08-16 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
A - Award 13,629 53,468 34.21
2024-08-20 2024-08-16 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
A - Award 5,275 39,839 15.26
2024-06-11 2024-06-10 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -975 34,564 -2.74 14.79 -14,420 511,202
2024-06-11 2024-06-08 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 1,893 35,539 5.63
2024-05-03 2024-05-02 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -3,503 32,053 -9.85 16.94 -59,341 542,978
2024-05-03 2024-05-01 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 6,814 35,556 23.71
2024-04-09 2024-04-08 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -2,716 28,742 -8.63 17.87 -48,535 513,620
2024-04-09 2024-04-05 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 5,275 31,458 20.15
2024-03-27 2024-03-27 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -5,434 26,183 -17.19 17.90 -97,269 468,676
2024-03-27 2024-03-25 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
A - Award 10,550 31,617 50.08
2024-02-27 2024-02-26 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -772 21,067 -3.53 24.67 -19,045 519,723
2024-02-27 2024-02-23 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 1,353 21,839 6.60
2023-11-21 2023-11-20 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -5,108 20,486 -19.96 22.64 -115,645 463,803
2023-11-21 2023-11-17 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 4,956 25,594 24.01
2023-11-21 2023-11-17 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 4,956 25,594 24.01
2023-08-23 2023-08-21 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -10,000 15,682 -38.94 29.00 -289,970 454,731
2023-06-12 2023-06-08 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -974 22,824 -4.09 25.02 -24,369 571,056
2023-06-12 2023-06-08 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 1,893 23,798 8.64
2023-05-19 2023-05-17 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -15,310 21,905 -41.14 22.50 -344,475 492,862
2023-05-19 2023-05-17 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 14,869 37,215 66.54
2023-05-19 2023-05-17 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 14,869 37,215 66.54
2023-04-07 2023-04-06 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -1,916 7,477 -20.40 18.16 -34,795 135,782
2023-04-07 2023-04-05 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 5,275 9,393 128.10
2023-02-27 2023-02-24 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -577 4,118 -12.29 18.78 -10,836 77,336
2023-02-27 2023-02-23 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 1,353 4,695 40.48
2022-06-10 2022-06-09 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -653 3,342 -16.35 17.91 -11,695 59,854
2022-06-10 2022-06-08 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 1,893 3,995 90.06
2022-04-07 2022-04-05 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
A - Award 21,101 21,101
2022-04-07 2022-04-05 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Options (Right to Buy)
A - Award 72,414 72,414
2022-02-25 2022-02-23 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise 1,352 4,059 49.94
2022-02-25 2022-02-23 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -553 2,102 -20.83 23.80 -13,161 50,028
2022-02-25 2022-02-23 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 1,352 2,655 103.76
2021-12-20 3 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
1,303
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)